Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)	B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Active, not recruiting	Phase 2	2026-09-15		NCT06647732

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Tongren Hospital	60
Fifth Affiliated Hospital of Guangzhou Medical University	17
Fifth Affiliated Hospital, Sun Yat-Sen University	41
Gansu Cancer Hospital	7
Huazhong University of Science and Technology	83
Shenzhen People's Hospital	35
Sun Yat-sen University	606
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University	Guangzhou	China	2